Evaluating The Clinical Efficacy Of Recombinant Human Interleukin-11 For Treatment Of Thrombocytopenia

Objective To study the relatoionship between thrombelatography variables in patients with thrombocytopenia after using recombinant human IL-11.Methods According to clinical diagnosis,60 patients whose thrombocyte were less than 70x109/L were randomly divided into the rhIL-11 group and control group.All the patients received active antibiotics and other comprehensive treatment.The rhIL-11 group was given rhIL-11 1.5mg/d,then compared with the results of platelet count ,coagulation fuction and thrombelastography.Results ?30 cases of RhIL-11 patients, including 19 cases of male, 11 cases of female, mean age is 55.33 + 5.57,mean APACHEII score is 20.8 + 7.8. The control group of 30 cases,including20 males and 10 females, mean age is 56.33 + 4.78, mean APACHEII score is22.3 + 6.5. The two groups had no statistically significant difference in gender and age of patients,APACHEII score. (P > 0.05). ?rhIL-11 group and control group, the platelet count before treatment had no significant difference (P > 0.05). Before and after treatment in two groups of coagulation four (prothrombin time,activated part prothrombin time,plasma thrombin time, fibrinogen r differences had no statistical significance difference. (P > 0.05) 7 days after treatment, platelet count of patients in the IL-11 group was higher than the control group at fifth day, there was significant difference between two groups (P < 0.05). Two groups of patients with thrombosis of thromboelastography related indexes in the treatment of no statistical significance (P > 0.05), rhIL-11 group before and after treatment, R, K, angle without obvious difference, the difference was not statistically significant (P > 0.05), increased after administration of Ma compared with that before treatment, the difference is statistically significant (P< 0.05).? In rhIL-11 group the total effective rate was 96.7%, control group total effective rate was 60%. The rhIL-11 group was significantly higher than the control group. ?The patients in the rhIL-11 group the average ICU stay time was 12 + 3.22 days, patients in the control group the average ICU stay time was 11.34 + 4.47 days. Two days in the ICU group was no statistically significant difference (P > 0.05). After 28 days, rhIL-11 group 10 cases died, the mortality rate was 33.3%. The control group 12 cases died, the mortality rate was 40%.The mortality rate between the two groups was not statistically significant. ?The ROC curve by ROC curve analysis, the MA value of the sensitivity and specificity were respectively 0.650, 0.733. ?The rhIL-11 group had no obvious adverse reactions.Conclusion The rhIL-11 can promote the recovery of the platelet count and fuction in the ICU thrombocytopenia patients,with its clinical efficacy safe and reliable.